Streetbeat News

Products Services

OCEA

Ocean Biomedical's share price target has been increased to $17.63 by Fundamental Research Corp. (FRC) following positive results from an independent study on glioblastoma tumor suppression, new patents, and recent financing. FRC's report highlights Ocean Biomedical's diversified development pipeline, which includes drug candidates for oncology, fibrosis, and infectious diseases.

Portfolio Pulse from Happy Mohamed

June 21, 2023 | 12:20 pm

DARE

Daré Bioscience announced the publication of data from a Phase 1/2 clinical trial of DARE-HRT1, a potential first FDA-approved monthly intravaginal ring for hormone therapy. The company plans to advance DARE-HRT1 into a single Phase 3 clinical trial for the treatment of vasomotor symptoms due to menopause.

Portfolio Pulse from Happy Mohamed

June 21, 2023 | 12:19 pm

OCUP

Ocuphire Pharma announced that Dr. Victor H. Gonzalez will present late breaking clinical data on APX3330 ZETA-1 at the American Diabetes Association Annual Conference. The presentation will focus on the efficacy and safety results of the ZETA-1 Phase 2 trial in diabetic retinopathy.

Portfolio Pulse from Happy Mohamed

June 21, 2023 | 12:18 pm

BWAY

BrainsWay Ltd. announced a significant expansion of its technology platform with an order of 30 new Deep Transcranial Magnetic Stimulation (Deep TMS) systems for the treatment of major depressive disorder (MDD) by a large TMS network of clinics in the Western and Central United States. Several systems also include an H7 Coil for obsessive-compulsive disorder (OCD) treatment.

Portfolio Pulse from Happy Mohamed

June 21, 2023 | 12:17 pm

ASAN

JUVF

ZNTL

Insider trades were observed in Zentalis Pharmaceuticals, Asana, and Juniata Valley Financial. Zentalis regained worldwide development and commercialization rights to azenosertib, ZN-d5, and ZN-c5 in Greater China. Asana reported better-than-expected Q1 financial results and issued Q2 EPS guidance above estimates. Juniata Valley Bank completed the purchase of Orrstown's Path Valley branch.

Portfolio Pulse from Lisa Levin

June 21, 2023 | 12:17 pm

ASMB

Assembly Biosciences presented new data on its hepatitis D and B virus antiviral pipeline at the International Liver Congress, showcasing promising results for its entry inhibitor and core inhibitor programs. The company expects to nominate a development candidate for its entry inhibitor program this year.

Portfolio Pulse from Happy Mohamed

June 21, 2023 | 12:16 pm

KULR

KULR Technology Group has signed a deal to conduct battery cell testing projects with a top 5 global eVTOL manufacturer. The tests, set to complete in Q3 2023, aim to advance eVTOL battery safety as federal regulators develop certification rules for the eVTOL air taxi market. KULR expects record revenues in Q2 2023.

Portfolio Pulse from Anusuya Lahiri

June 21, 2023 | 12:15 pm

KULR

KULR Technology has entered an agreement to undertake a series of battery cell testing projects with a manufacturer of electric vertical take-off and landing aircrafts.

Portfolio Pulse from Benzinga Newsdesk

June 21, 2023 | 12:15 pm

VRPX

Virpax Pharmaceuticals (NASDAQ: VRPX) has entered into a cooperative research and development agreement with the National Institute of Neurological Disorders and Stroke (NINDS). The partnership will focus on evaluating Virpax's NobrXiol product candidate for the management of rare pediatric epilepsy using a unique intranasal Molecular Envelope Technology (MET) delivery platform.

Portfolio Pulse from Happy Mohamed

June 21, 2023 | 12:14 pm

PETV

PetVivo Holdings has received an initial regulatory assessment for its proprietary Biomatrix Particulate Technology, which could lead to approval for various human products. The company plans to complete regulatory plans for new human products by the first part of 2024.

Portfolio Pulse from Happy Mohamed

June 21, 2023 | 12:13 pm